Related Experiment Videos
[Doxorubicin and cisplatin genotoxicity: search for a real indication using the micronucleus test]
F Duffaud1, T Orsière, M Baciuchka-Palmaro
1Service d'oncologie médicale, CHU La Timone Adultes, Marseille.
Abstract:
Doxorubicin and cisplatin are two major anticancer drugs, and are also known to be mutagen. Using short term mutagenesis tests, the cytokinesis-block micronucleus test and chromosome aberrations test, a study of the cytotoxicity and the mutagenicity of these two drugs has been aimed to determine a genotoxic of reference for these tests. Cisplatin and doxorubicin were genotoxic and gave positive results with the two tests. Since cisplatin was more cytotoxic than doxorubicin for a same genotoxicity, doxorubicin has been selected as a positive control for these two short-term mutagenesis tests. A study of the individual variability in the response to in vitro doxorubicin exposure was made using the cytokinesis-block micronucleus test, applied to cultured T lymphocytes form healthy subjects and cancer patients. Micronucleated cell rate before (T0) and after in vitro exposure to doxorubicin (T1) were determined in the two groups of subjects. Micronucleated cell rates T1 were significantly higher than T0 for healthy subjects and cancer patients. A calculated sensitivity index [(T1)-(T0)] is proposed to evaluate the individual sensitivity to the positive control doxorubicin.
Insights
Doxorubicin and cisplatin are mutagenic anticancer drugs. Doxorubicin was chosen as a reference genotoxic control for mutagenesis tests due to its lower cytotoxicity.
Area of Science:
- Genotoxicity testing
- Cancer drug evaluation
- Mutagenesis assays
Context:
- Anticancer drugs like doxorubicin and cisplatin are known mutagens.
- Short-term mutagenesis tests are crucial for evaluating drug genotoxicity.
- Establishing reliable positive controls is essential for assay validation.
Purpose:
- To determine a suitable genotoxic reference standard for short-term mutagenesis tests.
- To compare the cytotoxicity and mutagenicity of doxorubicin and cisplatin.
- To assess individual variability in T lymphocyte response to doxorubicin.
Summary:
- Both doxorubicin and cisplatin demonstrated genotoxicity in cytokinesis-block micronucleus and chromosome aberration tests.
- Doxorubicin was selected as the positive control due to its lower cytotoxicity compared to cisplatin at equivalent genotoxic levels.
- The study evaluated individual sensitivity to doxorubicin in T lymphocytes from healthy and cancer patients, proposing a sensitivity index.
Impact:
- Provides a validated positive control (doxorubicin) for short-term genotoxicity assays.
- Highlights the potential for individual variability in response to genotoxic agents.
- Contributes to the accurate assessment of drug-induced genetic damage in cancer therapy research.